Phio Pharmaceuticals names David Deming lead independent director, boosting governance and investor confidence amid growing analyst coverage in biotech.

Phio Pharmaceuticals Corp is a biotechnology company dedicated to developing innovative cancer treatments and other healthcare solutions, with a focus on patient care and accessibility.

Phio Pharmaceuticals Corp’s stock has experienced significant volatility, with a 52-week high nearly ten times its current value, raising concerns about the company’s financial health and potential undervaluation.